MUC1 is a Potential Target to Overcome Trastuzumab Resistance in Breast Cancer Therapy

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2022 Mar 6

PMID 35248049

Authors

Aysooda Hosseinzadeh

Parnaz Merikhian

Nazanin Naseri

Mohammad Reza Eisavand

Leila Farahmand

Affiliations

Soon will be listed here.

Abstract

Although resistance is its major obstacle in cancer therapy, trastuzumab is the most successful agent in treating epidermal growth factor receptor 2 positive (HER2 +) breast cancer (BC). Some patients show resistance to trastuzumab, and scientists want to circumvent this problem. This review elaborately discusses possible resistance mechanisms to trastuzumab and introduces mucin 1 (MUC1) as a potential target efficient for overcoming such resistance. MUC1 belongs to the mucin family, playing the oncogenic/mitogenic roles in cancer cells and interacting with several other oncogenic receptors and pathways, such as HER2, β-catenin, NF-κB, and estrogen receptor (ERα). Besides, it has been established that MUC1- Cytoplasmic Domain (MUC1-CD) accelerates the development of resistance to trastuzumab and that silencing MUC1-C proto-oncogene is associated with increased sensitivity of HER2 cells to trastuzumab-induced growth inhibitors. We mention why targeting MUC1 can be useful in overcoming trastuzumab resistance in cancer therapy.

Citing Articles

A mini-review-cancer energy reprogramming on drug resistance and immune response.

Liu C, Yang L, Gao T, Yuan X, Bajinka O, Wang K Transl Oncol. 2024; 49:102099.

PMID: 39163759 PMC: 11380382. DOI: 10.1016/j.tranon.2024.102099.

Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.

Ayyalasomayajula R, Cudic M Cancers (Basel). 2024; 16(7).

PMID: 38611013 PMC: 11011055. DOI: 10.3390/cancers16071334.

Inhibition of breast cancer cell growth and migration through siRNA-mediated modulation of circ_0009910/miR-145-5p/MUC1 axis.

Abtin M, Nafisi N, Hosseinzadeh A, Kadkhoda S, Omranipour R, Sahebi L Noncoding RNA Res. 2024; 9(2):367-375.

PMID: 38511058 PMC: 10950563. DOI: 10.1016/j.ncrna.2024.01.016.

In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla.

Guz W, Podgorski R, Bober Z, Aebisher D, Truszkiewicz A, Olek M Int J Mol Sci. 2024; 25(3).

PMID: 38338997 PMC: 10855746. DOI: 10.3390/ijms25031719.

MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma.

Xu H, Du Z, Li Z, Liu X, Li X, Zhang X Ann Med. 2024; 56(1):2313671.

PMID: 38325364 PMC: 10851807. DOI: 10.1080/07853890.2024.2313671.

References

Ren J, Agata N, Chen D, Li Y, Yu W, Huang L . Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004; 5(2):163-75. PMC: 4217165. DOI: 10.1016/s1535-6108(04)00020-0. View

Gornowicz A, Bielawska A, Szymanowski W, Gabryel-Porowska H, Czarnomysy R, Bielawski K . Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells. Oncol Lett. 2018; 15(2):2340-2348. PMC: 5776928. DOI: 10.3892/ol.2017.7623. View

Mohebtash M, Tsang K, Madan R, Huen N, Poole D, Jochems C . A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011; 17(22):7164-73. PMC: 3227395. DOI: 10.1158/1078-0432.CCR-11-0649. View

Ortega M, Fraile-Martinez O, Asunsolo A, Bujan J, Garcia-Honduvilla N, Coca S . Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J Oncol. 2020; 2020:9258396. PMC: 7085392. DOI: 10.1155/2020/9258396. View

Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S . A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 2014; 14(3):154-60. DOI: 10.1016/j.clbc.2013.12.012. View

Ma J, Qin L, Li X . Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020; 18(1):33. PMC: 7048131. DOI: 10.1186/s12964-020-0527-z. View

Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D . Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Mol Cancer Res. 2013; 11(7):714-23. PMC: 3720729. DOI: 10.1158/1541-7786.MCR-12-0668. View

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G . Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019; 20(3):371-382. DOI: 10.1016/S1470-2045(18)30812-X. View

Taylor-Papadimitriou J, Burchell J, Miles D, Dalziel M . MUC1 and cancer. Biochim Biophys Acta. 1999; 1455(2-3):301-13. DOI: 10.1016/s0925-4439(99)00055-1. View

10.

Li Y, Yu W, Ren J, Chen W, Huang L, Kharbanda S . Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003; 1(10):765-75. View

11.

Baselga J, Gelmon K, Verma S, Wardley A, Conte P, Miles D . Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 28(7):1138-44. PMC: 4979216. DOI: 10.1200/JCO.2009.24.2024. View

12.

Raina D, Agarwal P, Lee J, Bharti A, McKnight C, Sharma P . Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156. PMC: 4534190. DOI: 10.1371/journal.pone.0135156. View

13.

Ling J, Kumar R . Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett. 2012; 322(2):119-26. DOI: 10.1016/j.canlet.2012.02.033. View

14.

Kufe D . Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009; 9(12):874-85. PMC: 2951677. DOI: 10.1038/nrc2761. View

15.

OSullivan C, Connolly R . Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. Oncology (Williston Park). 2014; 28(3):186-94, 196. View

16.

Huang Y, Fu P, Fan W . Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer. Curr Drug Targets. 2013; 14(8):889-98. DOI: 10.2174/13894501113149990161. View

17.

Dillon L, Bean J, Yang W, Shee K, Symonds L, Balko J . P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 2014; 34(30):3968-76. PMC: 4387124. DOI: 10.1038/onc.2014.328. View

18.

Yin L, Huang L, Kufe D . MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem. 2004; 279(44):45721-7. DOI: 10.1074/jbc.M408027200. View

19.

Shao Y, Sun X, He Y, Liu C, Liu H . Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS One. 2015; 10(7):e0133830. PMC: 4514648. DOI: 10.1371/journal.pone.0133830. View

20.

Miles D, Roche H, Martin M, Perren T, Cameron D, Glaspy J . Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMC: 3228158. DOI: 10.1634/theoncologist.2010-0307. View